Q3 Revenue Jumps 68% to $33.5M, Full-Year Guidance Raised to $121-123M
ALMR sits 67% above its 52-week low of $18.845.
Summary
Alamar posted Q3 2026 revenue of $33.5 million, up 68% from $19.9 million a year ago, and lifted full-year 2026 guidance to $121-123 million from the prior $116-120 million. That is roughly 64% growth at the midpoint and a clear step up from the Q2 print of $29.4 million (+82%) that sent shares up 33.78% in August. Gross margin improved to 61.5% from 59.7%, but operating expenses jumped 81% to $35.8 million and the operating loss widened to $15.1 million from $7.9 million, with stock-based compensation at $3.9 million. The quarter also brought a UK Biobank selection to profile 80,000 samples and a GSK collaboration on a 60,000-sample study, both supporting the biopharma demand story. Separately, President Tod White will retire at year-end and stay on as an advisor through June 2027. Cash and investments stood at $231.5 million as of September 30.
At the time of this announcement, ALMR was trading at $31.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $18.85 to $39.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.